#Leap therapeutics trial#

So I would say they will need more cash roughly 8 quarters from now. However, once phase 3 trials start, the cash burn will substantially increase. At current cash burn rates of roughly $10mn per quarter, they have cash enough for 10 quarters. The $90mn raise adds substantially to their cash runway.

The dilution wasn’t able to dampen the stock’s surge the offered price was $2.85 but the stock is trading today at $3.59. At that rate, they have/had cash for only 3-4 quarters left, but they played it smart and raised some cash through a $90mn secondary and warrants offering as the stock soared. Research and development expenses were $7.2 million for the second quarter 2021, while General and administrative expenses were $2.8 million. LEAP has a market cap of $300mn and a cash reserve of $35mn as of June.

#Leap therapeutics trial#

The study will be completed by December 2021, which may be an important near-term catalyst for the stock.Įarlier this year, DKN-01 also showed positive data in a phase 2a trial in patients with either epithelial endometrial cancer, epithelial ovarian cancer, or carcinosarcoma. However that may be, the September data saw the stock bounce nearly 50% in a single trading day. Recall, though, that there were 5 drug-related adverse events with grades greater than or equal to 3 one grade 5 AE presented with pulmonary embolism. The drug had an acceptable safety profile given the advanced stage of the patient population. Just last month, at ESMO 2021, the company presented data from the DisTinGuish trial. DKN-01 also increases PD-L1 expression and has an additive effect with anti-PD1s across a variety of cancers. In preclinical studies, DKK1 inhibition using DKN-01 has shown to reverse tumerogenic microenvironment and inhibit pro-cancerous P13K/AKT signalling. Studies have shown an increase in the dkk1 protein in the serum of multiple myeloma patients, and successful treatment with HSCT has shown a decrease in serum Dkk1. Dkk is primarily a Wnt modulator, and since Wnts play a singular role in oncogenesis, there’s ample reason to believe that Dkk is an important therapeutic target for cancer.

Like so many other active protein-producing genes that also have a deleterious effect when it comes to cancer, the Dkk gene is implicated in cancer. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer's disease. Dkks play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero–posterior axial patterning, limb development, somitogenesis and eye formation. Additionally, Dkks are high affinity ligands for the transmembrane proteins Kremen1 and 2, which also modulate Wnt signaling. They encode secreted proteins that typically antagonize Wnt/β-catenin signaling, by inhibiting the Wnt coreceptors Lrp5 and 6. There is one other asset though, TRX518, however, it is still in preclinical stage.ĭickkopf (Dkk) genes comprise an evolutionary conserved small gene family of four members (Dkk1-4) and a unique Dkk3-related gene, Dkkl1 (soggy). Its pipeline looks like this:ĭespite that list, Leap has only one asset, DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.

Leap Therapeutics ( NASDAQ: LPTX) is a relatively unknown cancer therapeutics company with a bunch of assets in midstage trials.